Hit the lenti characterization jackpot with RNA detection on Leprechaun

The Problem

Getting an early read on the titer of intact, RNA-containing lentivirus in a batch is vital for optimizing cell therapy manufacture. Too bad most current methods only work with the purest samples and can’t check how many viral particles contain both capsid and RNA. This makes it impossible to get an accurate lentivirus titer immune to fragmented or damaged viral particles and contaminants.

The Solution

Leprechaun is the only tool that provides complete biophysical characterization of individual lentivirus particles from crude harvest to final product. Using <25 µL sample Leprechaun pairs up single particle sizing with fluorescence microscopy to directly check how many viral particles are the right size, have the correct envelope protein, and contain both capsid and RNA. For the first time ever, you can get an accurate titer of structurally complete, RNA-containing lentivirus at every step of your process.

The Proof

In this webinar you’ll learn how Leprechaun isolates lentivirus from even the crudest samples, checks each virus for capsid and RNA, and sizes everything up to separate aggregates from single viruses. We’ll look at multiple lentivirus batches to show how Leprechaun can help ID the highest quality samples early on, and compare samples from different purification stages to shed light on what’s really going on during your purification process. Revolutionize your lentiviral analytics with Leprechaun and ensure your preps always meet the highest standard.

Presenter: Taegen Clary (SVP Sales & Marketing, Unchained Labs)

Taegen loves marketing life science tools. He has over 15 years of experience using and marketing enabling life science instrumentation and consumables. As the Director of Pharmaceutical Segment Marketing at Agilent Technologies, he led the marketing organization focused on the company’s largest customer segment, which has experienced consistent, above-market growth rates and 2014 sales revenues of $1B.

Over his 7 years at Agilent, Taegen was the Product Manager for Proteomics and Protein Chemistries and also led the Life Science group’s efforts in the area of protein therapeutics. He began his career at Berlex Biosciences, now a part of Bayer Healthcare, running mass spectrometers and developing assays to measure drug passage across the blood brain barrier.

Taegen has an M.B.A. in Marketing from St. Mary’s College of California and a B.S. in Biotechnology from the University of California, Davis. Taegen is married with two children, loves mountain biking, camping, fishing, golfing and is a huge fan of the San Francisco Giants and 49ers.

Presenter: Alex Shephard (Market Manager, Cell Therapy at Unchained Labs)

Alex Shephard is the Market Manager for Cell Therapy at Unchained Labs. She has many years of experience at the bench and as a field application scientist characterizing exosomes and viruses, using techniques including NTA, DLS, nanoflow cytometry and interferometry. Alex completed a Ph.D. in Molecular Biology at Bristol University, UK, and held a postdoc position in the Tumour Microenvironment Group at Cardiff University, UK.